US judge dismisses FTC (Federal Trade Commission) fraud case against VISX
This article was originally published in Clinica
Executive Summary
A US judge has ordered the dismissal of the Federal Trade Commission's patent fraud case against ophthalmic laser company VISX. The ruling supports an earlier decision where the judge had found in favour of VISX regarding three patents. Shares in VISX rose over 27% on the news.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.